AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00399308 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celaderm (Frozen Cultured Epidermal Allograft)
Description: Four biweekly applications of Celaderm plus compression therapy
Study NCT00399308 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celaderm (Frozen Cultured Epidermal Allograft)
Description: Four weekly applications of Celaderm plus compression therapy
Study NCT00399308 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control (compression bandaging)
Description: Multi-layer compression bandaging
Study NCT03874338 — intervention group
Intervention type: DRUG
Intervention: Colchicine Pill
Description: Participants in the main CLEAR SYNERGY trial are randomized to colchicine/spironolactone versus placebo in a 2x2 factorial design. The substudy is interested in the evaluation of biospecimens obtained from patients in the colchicine vs placebo group.
Study NCT05882591 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posteromedial Tibiofemoral Incongruence (PMTFI) Treatment by the means of published technique (reference nr 1).
Description: Posteromedial Tibiofemoral Incongruence (PMTFI) Treatment by the means of published technique (reference nr 1).
Study NCT02027155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AR09 solution
Description: moderate levels of sedation
Study NCT02027155 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AR09 solution
Description: moderate levels of sedation
Study NCT02027155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Sterile Saline, USP
Study NCT02027155 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Sterile Saline, USP
Study NCT03240601 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal stimulation
Description: For TSS, a transcutaneous electrical nerve stimulation (TENS) unit is used. A 2 inch diameter round electrode is placed on the skin over T11/T12 (cathode), and a large butterfly electrode is placed on the skin over the umbilicus (anode). Pulse width is set to 400 microseconds at 50 Hz.
Study NCT03240601 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous spinal stimulation
Description: For TSS, a transcutaneous electrical nerve stimulation (TENS) unit is used. A 2 inch diameter round electrode is placed on the skin over T11/T12 (cathode), and a large butterfly electrode is placed on the skin over the umbilicus (anode). Pulse width is set to 400 microseconds at 50 Hz.
Study NCT03589716 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vital Moto Mod
Description: All participants receive vital signs measurement using the Vital Moto Mod device and reference devices. The vital signs measured are blood pressure, heart rate, respiratory rate, oxygen saturation and temperature.
Study NCT03589716 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Welch Allyn Connex Spot Vital Signs Monitor
Description: This is the FDA approved reference device to measure heart rate, SpO2 and temperature.
Study NCT03235284 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nintendo Wii
Description: Nintendo Wii program (GW) based on the use of the NW for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes.~The GW treatment program consists of the following protocols: a) protocol 1 games (Boxing and Soccer); b) protocol 2 games (Golf and running). 20 minutes for each game
Study NCT03235284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises and Nintendo Wii
Description: In GCW program will be performed 20 minutes GC protocol (1 or 2, used alternately between sessions a week) and 20 minutes GW protocol (1 or 2, used alternately between sessions a week), taking the time of the performed activities halved in both protocols
Study NCT03476707 — intervention group
Intervention type: OTHER
Intervention: Anemia
Description: Hematocrit less than 0.39
Study NCT01051830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes interdisciplinary program
Description: Diabetes consulting, rehabilitation program
Study NCT00201890 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphatic Massage (Decongestive Lymphatic Therapy) (Arm 1)
Description: 20 weeks of lymphatic massage therapy by a certified LMT in the Vodder technique Elastic Compression Sleeve and GLove
Study NCT02898415 — intervention group
Intervention type: PROCEDURE
Intervention: Liver transplantation
Study NCT01277900 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic Roux en Y gastric Bypass
Description: Laparoscopic Roux-en-Y gastric bypass will be used as a standard procedure to treat type 2 diabetes mellitus
Study NCT03589716 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Capnostream 20 Portable Bedside Capnograph
Description: This is the reference device to be used to obtain etCO2 waveforms for respiratory rate assessment.
Study NCT03589716 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Welch Allyn 767 Mobile Aneroid Sphygmomanometerand 3M Littmann Master Classic II Teaching Stethoscope
Description: These reference devices will be used together for blood pressure measurements.
Study NCT03589716 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Scifit 1000R cycle ergometer
Description: This is the device that will be used for exercise testing
Study NCT01404741 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic stem cell transplantation
Description: donor available, after 4 cycles 5-azacytidine allogeneic stem cell transplantation after reduced conditioning
Study NCT02111187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LDE225
Description: Sonidegib was given as an oral drug at 800mg daily for 28 days prior to prostetoctomy
Study NCT01404741 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 5-azacytidine until progress
Description: if no donor available 5-azacytidine until progress or toxicities
Study NCT00904969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The AMS Male Transobturator Sling System
Description: The AMS Male Transobturator Sling System was developed to treat urinary stress incontinence in men resulting from intrinsic sphincter deficiency (ISD) secondary to radical prostatectomy. The Male Transobturator Sling System procedure is minimally invasive and consists of using two single-use needle passers and passing them through two small incisions over the obturator foramen. The needles are pushed in an arc through the tissue and exited at a perineal incision. Once the passers are through the perineal incision, the Sling System mesh arms are attached to the needles which are then pulled back through the needle track to their points of origin over the obturator foramen. The Sling System is subsequently tensioned and all incisions are closed.
Study NCT00904969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AdVance Male Sling
Description: A transobturator sling for the treatment of post-prostatectomy incontinence
Study NCT04267354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm cycling
Description: The arm cycle will be placed on table with height adjusted to be the same as the acromion (highest point on shoulder). Participants will start arm cycling at a low intensity and increase as per tolerance. They will exercise for a maximum of two minutes at a time, followed by a rest period for 30 seconds. In this manner 5 cycles of exercise and rest will be performed. The exercise sessions are anticipated to last a maximum of 20 minutes, depending on the patient's abilities.
Study NCT01843829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT01843829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study NCT01843829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT01843829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT01843829 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study NCT01843829 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Patients will have their tumour surgically removed by two-phase oesophagectomy and two-field lymphadenectomy.
Study NCT01910285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanyl - sufentanil placebo
Description: Induction of general anesthesia with 3 mg/kg of propofol combined with 3 µg/kg of remifentanil and 10 ml of isotonic sodium chloride for the double blind. The trachea is then intubated after waiting the time of action of each product.
Study NCT01910285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil - remifentanyl placebo
Description: Induction of general anesthesia with 3 mg/kg of propofol combined with 0.3 mg/kg of sufentanil and 25 ml of isotonic sodium chloride for the double blind. The trachea is then intubated after waiting the time of action of each product.
Study NCT00433173 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: intravenous glucose tolerance test
Description: The IVGTT (70) is a 4 hour study with baseline sampling for insulin and glucose, followed by the administration of 0.3 mg/kg infusion of glucose, and subsequent frequent samples through 180 minutes. At 20 minutes, subjects will receive a 0.03 U/kg infusion of regular human insulin over 45 seconds to enhance the insulin level to better help us assess the impact of insulin on glucose uptake and to facilitate minimal model analysis. The IVGTT will be administered at baseline and after 3 months.
Study NCT00433173 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravenous glucose tolerance test
Description: The IVGTT (70) is a 4 hour study with baseline sampling for insulin and glucose, followed by the administration of 0.3 mg/kg infusion of glucose, and subsequent frequent samples through 180 minutes. At 20 minutes, subjects will receive a 0.03 U/kg infusion of regular human insulin over 45 seconds to enhance the insulin level to better help us assess the impact of insulin on glucose uptake and to facilitate minimal model analysis. The IVGTT will be administered at baseline and after 3 months.
Study NCT00433173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: testosterone
Description: transdermal 7.5 g/per day for 3 months
Study NCT00433173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anastrozole
Description: tablet (per oral) 10.0 mg/ daily 3 months
Study NCT00433173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: goserelin acetate implant
Description: single depot injection 10.8 mg 3 months
Study NCT00433173 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: aerobic capacity (VO2 Max)
Description: This test is employed to assess VO2max in all subjects. O2 and CO2 will be collected and measured from the expired air during the exercise stress test and used to calculate VO2max. This test will be administered at baseline and after 3 months.
Study NCT00433173 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: aerobic capacity (VO2 Max)
Description: This test is employed to assess VO2max in all subjects. O2 and CO2 will be collected and measured from the expired air during the exercise stress test and used to calculate VO2max. This test will be administered at baseline and after 3 months.
Study NCT00433173 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: MRI
Description: 1H-MR spectroscopy will be performed to measure IMCL at baseline and after 3 months.
Study NCT00433173 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: 1H-MR spectroscopy will be performed to measure IMCL at baseline and after 3 months.
Study NCT00433173 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: muscle biopsy
Description: Biopsies (20-50mg) will be obtained from the vastus lateralis muscle under local anesthesia (1% lidocaine) using a 5 mm Bergström needle (65) with suction applied. The muscle biopsy will be performed at baseline and after 3 months.
Study NCT00433173 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: muscle biopsy
Description: Biopsies (20-50mg) will be obtained from the vastus lateralis muscle under local anesthesia (1% lidocaine) using a 5 mm Bergström needle (65) with suction applied. The muscle biopsy will be performed at baseline and after 3 months.
Study NCT00433173 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: measurement of resting metabolic rate (energy expenditure)
Description: Energy expenditure in the form of resting metabolic rate (RMR) will be measured via a metabolic monitor at baseline and after 3 months.
Study NCT00433173 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: measurement of resting metabolic rate (energy expenditure)
Description: Energy expenditure in the form of resting metabolic rate (RMR) will be measured via a metabolic monitor at baseline and after 3 months.
Study NCT00433173 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Dual energy x-ray absorptiometry
Description: Total and regional percent body fat, fat mass, lean tissue mass and bone mineral content will be determined by DEXA (Lunar Prodigy version 8.50). DEXA provides an in vivo assessment of body composition with minimal requirements for subject cooperation and will be employed at baseline and after 3 months.
Study NCT00433173 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dual energy x-ray absorptiometry
Description: Total and regional percent body fat, fat mass, lean tissue mass and bone mineral content will be determined by DEXA (Lunar Prodigy version 8.50). DEXA provides an in vivo assessment of body composition with minimal requirements for subject cooperation and will be employed at baseline and after 3 months.
Study NCT00433173 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Fasting oral glucose tolerance test
Description: To examine glucose and insulin metabolism a standard 75g OGTT will be conducted at baseline and after 3 months.
Study NCT00433173 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fasting oral glucose tolerance test
Description: To examine glucose and insulin metabolism a standard 75g OGTT will be conducted at baseline and after 3 months.
Study NCT02137746 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cells DCVAC/PCa
Description: DCVAC/PCa Experimental therapy
Study NCT03074136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photodinamic therapy
Description: Dentin sealant (HELBO® Endo Seal, Bredent, Senden, Germany) will be applied over the crown area and light cured. The root canals will be filled with the phenothiazine chloride (HELBO® Endo Blue, Bredent, Senden, Germany), agitated with a size 15K-file and left in the canal for 2 min. After this time, the root canals will be rinsed with distilled water to remove the excess of the photosensitizer, dried with paper points. The disposable 450 µm fiberoptic tip (3D HELBO® Endo Probe, Bredent, Senden, Germany) will be placed in the apical portion of the root canal at the point where resistance to the fiber will be felt, and root canal will be irradiated with HELBO® TheraLite Laser (λ = 660 nm, power = 100 mW) for 60 s (total energy, 6 J) in a continuous wave mode.
Study NCT03074136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode laser
Description: High-power diode laser therapy will be applied by using Epic diode laser (Biolase® Technology, Inc., San Clemente, CA, USA) with settings determined in laboratory researches (λ = 940 nm, maximal power 10W).
Study NCT03074136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% Sodium hypochlorite
Description: Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degrees Celsius).
Study NCT02473848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ingenol mebutate 500 ucg
Description: Ingenol mebutate gel, 0.05%, commercially supplied in a box of 2 single use, unit dose tubes for topical application for each 25cm2, four conjunctive 25cm2 areas (100cm2) will be treated. If the 100 cm2 area is not cleared at Day 57 (+/- 3 Days), a second treatment cycle will be initiated with commercially supplied drug in a box of 2 single use, unit dose tubes for topical application for each 25cm2 and four conjunctive 25cm2 areas (100cm2 ) will be treated. In total for the first cycle, 4 commercially supplied boxes (8 unit dose tubes) will be used, and for the second cycle an additional 4 commercially supplied boxes (8 unit dose tubes) will be used (in total 8 boxes, 16 unit dose tubes per patient).
Study NCT00603408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT00603408 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Study NCT00603408 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mastectomy
Description: (RECOMMENDED BUT NOT REQUIRED)
Study NCT04985617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warmed Fluids
Description: The IV fluid given to the patients in the intervention group was heated to 36ºC using the medical heating device.
Study NCT04762121 — intervention group
Intervention type: PROCEDURE
Intervention: Peripheral IV
Description: Insertion of peripheral intravenous catheter
Study NCT04847193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention 1: Placebo
Description: Participants receive a study drink supplemented with a placebo for 5 days
Study NCT04847193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention 2: Xanthohumol and Iso-alpha acids
Description: Participants receive a study drink supplemented with xanthohumol, Iso-alpha acids or a combination of both for 5 days
Study NCT01221896 — intervention group
Intervention type: PROCEDURE
Intervention: C11-Choline PET/CT
Study NCT04450238 — intervention group
Intervention type: BEHAVIORAL
Intervention: Routine care inpatient treatment
Description: All participants are receiving inpatient treatment consisting of a variety of psychological interventions such as cognitive-behavioral therapy, third-wave interventions, psycho-education and in some cases medication.
Study NCT00425269 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle intervention (diet and physical activity)
Description: The intervention will include a combination of individual counselling group sessions. The intervention groups will be divided into subgroups of 10-12 subjects. Each group will have 10 group sessions on diet/lifestyle in the 6 months the intervention period lasts, and will additionally have the possibility to join a culturally adapted exercise program of low intensity twice a week.
Study NCT01140529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Bolus and continuous infusion
Study NCT01140529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Bolus doses
Study NCT01140529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Bolus and continuous infusion
Study NCT00281463 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pushrim Activated Power Assist
Description: The PAPAW is an electrically-powered add-on unit for common manual wheelchairs. The unit automatically supplements the users manual pushrim input with additional rear-wheel torque for up to six kilometers/hour traveling velocity. The amount of added torque is provided proportional to the user input to the pushrims. Movement and braking assistance is provided for both forward and rearward travel. Several types and sizes are available based on users operating strength, needs and anthropometry. The PAPAWs to be tested during this study will be the JWII (Yamaha Motor Corporation).
Study NCT03544749 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu® AuraGain™
Description: After induction of anesthesia, Ambu® AuraGain™ will be inserted for the mechanical ventilation.
Study NCT03544749 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-gel
Description: After induction of anesthesia, I-gel will be inserted for the mechanical ventilation.
Study NCT05165134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotape
Description: Elastic tape used for mechanical correction of the deformity in study group and placebo in control group
Study NCT05165134 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Kinesiotape
Description: Elastic tape used for mechanical correction of the deformity in study group and placebo in control group
Study NCT01423175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine, ara-C
Study NCT01423175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLAMSA
Study NCT04456504 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant hepatitis B vaccine with CpG adjuvant
Description: Each participant will receive two doses of hepB-CpG separated by one month and blood draw to measure antibody to the hepatitis B surface antigen prior to dose 2 and one month after dose 2.
Study NCT01703910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm A chemotherapy
Study NCT01703910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arm B chemotherapy
Study NCT01666249 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunoglobulin Anti-RhD
Description: Participants will receive a single intramuscular administration of 300 mcg/2mL, correponding 1500 UI of Human Immunoglobulin Anti-RhD (Kamrho-D - Panamerican), up to 72 hours post exposition (child-birth).